Astressin is a potent corticotropin releasing factor (CRF) antagonist.
CAT No: R1219
CAS No:170809-51-5
Synonyms/Alias:Astressin;170809-51-5;CHEBI:76649;MFCD00798715;fHLLREVLE-Nle-ARAEQLAQ-cyclo-(EAHK)NRKL-Nle-EII-NH2;[D-Phe(12), Nle(21,38), Glu(30), Lys(33)]-CRF (12-41);D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-cyclo-(Glu-Ala-His-Lys)-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2;Astressin trifluoroacetate salt;(D-Phe(12), Nle(21,38), Glu(30), Lys(33))-CRF (12-41);Cyclo(30-33)(phe(12),nle(21,38),glu(30),lys(33))r-hcrf(12-41);GTPL925;GLXC-27962;AKOS024456701;FA108999;D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-cyclo[Glu-Glu-Ala-His-Lys]-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2;H-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-cyclo(-Glu-Ala-His-Lys)- Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile -NH2; H-(dF)HLLREVLE(Nle)ARAEQLAQ[Bbc][EAHK]NRKL(Nle)EII-NH2;L-Isoleucinamide, D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-arginyl-L-alpha-glutamyl-L-valyl-L-leucyl-L-alpha-glutamyl-L-norleucyl-L-alanyl-L-arginyl-L-alanyl-L-alpha-glutamyl-L-glutaminyl-L-leucyl-L-alanyl-L-glutaminyl-L-alpha-glutamyl-L-alanyl-L-histidyl-L-lysyl-L-asparaginyl-L-argin;L-Isoleucinamide,d-phenylalanyl-L-histidyl-L-Leucyl-L-Leucyl-L-arginyl-L-a-glutamyl-L-valyl-L-Leucyl-L-a-glutamyl-L-norleucyl-L-alanyl-L-arginyl-L-alanyl-L-a-glutamyl-L-glutaminyl-l-leucyl-l-alanyl-l-;
Astressin is a synthetic peptide antagonist of corticotropin-releasing factor (CRF) receptors, designed to modulate the activity of CRF signaling pathways in various biological systems. As a non-selective blocker of both CRF1 and CRF2 receptor subtypes, Astressin is widely recognized within the field of neuroendocrinology for its ability to inhibit stress-mediated responses at the molecular level. Its robust peptide structure and high receptor affinity make it a valuable tool for dissecting the physiological and biochemical roles of CRF in both central and peripheral tissues. Researchers leverage Astressin to explore the molecular underpinnings of stress, investigate peptide-receptor interactions, and elucidate downstream signaling mechanisms relevant to a range of biological processes.
Neuroendocrine research: Astressin is extensively utilized in studies focused on the hypothalamic-pituitary-adrenal (HPA) axis and its regulation by CRF. By selectively antagonizing CRF receptors, it enables researchers to delineate the contribution of CRF signaling to the secretion of adrenocorticotropic hormone (ACTH) and subsequent glucocorticoid production. This application is fundamental for understanding how stress-related neuropeptides drive endocrine responses, providing insights into the molecular circuitry governing homeostasis and adaptation to environmental challenges.
Behavioral neuroscience: As a potent CRF receptor antagonist, Astressin is employed to investigate the neurobiological basis of stress and anxiety-like behaviors in animal models. Its use allows for the modulation of CRF-mediated neurotransmission in the central nervous system, offering a means to probe the behavioral consequences of altered peptide signaling. Such studies are instrumental in identifying the neural circuits and molecular targets involved in affective and cognitive processes, advancing the broader understanding of stress-related behavioral phenotypes.
Peptide-receptor interaction studies: The high specificity and affinity of Astressin for CRF receptors make it an ideal probe for characterizing ligand-receptor binding dynamics. In vitro assays and receptor binding studies utilize this peptide to map binding sites, assess receptor subtype selectivity, and quantify antagonist potency. These investigations are critical for elucidating the structural determinants of peptide-receptor recognition and for informing the rational design of novel CRF pathway modulators.
Cell signaling analysis: Astressin's ability to block CRF-induced intracellular signaling cascades is leveraged in cell-based assays to dissect downstream molecular events. By inhibiting CRF receptor activation, it permits the study of second messenger systems, such as cyclic AMP pathways, and the identification of transcriptional responses triggered by CRF signaling. This application supports mechanistic research into GPCR-mediated signal transduction and the cellular effects of peptide hormone antagonism.
Peptide synthesis and analytical validation: In addition to its functional roles in biological assays, Astressin serves as a reference compound in the synthesis, purification, and analytical validation of CRF-related peptides. Laboratories utilize it as a standard for quality control, assay calibration, and comparative analysis, ensuring the reliability and reproducibility of peptide-based experimental workflows. Its well-characterized structure and activity profile contribute to method development and optimization in peptide chemistry and biochemical research contexts.
1. Implications of ligand-receptor binding kinetics on GLP-1R signalling
3. Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors
4. High fat diet and GLP-1 drugs induce pancreatic injury in mice
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More